Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study
Open Access
- 24 July 2018
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 35 (8) , 1153-1168
Abstract
To assess the impact of certolizumab pegol (CZP) treatment on clinical, patient-reported, and musculoskeletal ultrasound outcomes and to determine the treatment response time point most predictive of long-term outcomes in Italian patients with rheumatoid arthritis (RA).Keywords
Funding Information
- UCB Pharma
This publication has 55 references indexed in Scilit:
- PEGylated drugs in rheumatology--why develop them and do they work?Rheumatology, 2013
- EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2013
- Role of ultrasonography in diagnosing early rheumatoid arthritis and remission of rheumatoid arthritis - a systematic review of the literatureArthritis Research & Therapy, 2013
- Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled studyArthritis Research & Therapy, 2012
- Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 TrialThe Journal of Rheumatology, 2012
- Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled TrialThe Journal of Rheumatology, 2011
- Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trialArthritis Research & Therapy, 2009
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialAnnals of the Rheumatic Diseases, 2009
- Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonographyClinical Rheumatology, 2007
- Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanerceptAnnals of the Rheumatic Diseases, 2005